Skip to main content

Table 2 Summary of tumor response and survival data

From: Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

Best overall response

Patients

CR*, n (%)

0(0)

PR*, n (%)

15(50.0)

SD*, n (%)

8(26.7)

PD*, n (%)

5(16.7)

NE*, n (%)

2(6.7)

ORR*, n (%)

15/28(53.6)

DCR*, n (%)

23/28(82.1)

DOR* (months), median (95% CI*)

8.8(6.0-11.5)

PFS* (months), median (95% CI)

8.5(5.4–11.5)

OS* (months), median (95% CI)

12.5(3.7–21.3)

  1. *CR: Complete response
  2. PR: Partial response
  3. SD: Stable disease
  4. PD: Progressive disease
  5. NE: Not evaluable
  6. ORR: Objective response rate
  7. DCR: Disease control rate
  8. DOR: Duration of response
  9. PFS: Progression Free Survival
  10. OS: Overall Survival
  11. CI: Confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us